Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

392 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
Chesney J, Awasthi S, Curti B, Hutchins L, Linette G, Triozzi P, Tan MCB, Brown RE, Nemunaitis J, Whitman E, Windham C, Lutzky J, Downey GF, Batty N, Amatruda T. Chesney J, et al. Among authors: nemunaitis j. Melanoma Res. 2018 Feb;28(1):44-51. doi: 10.1097/CMR.0000000000000399. Melanoma Res. 2018. PMID: 29176501 Clinical Trial.
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
Hong DS, Kurzrock R, Wheler JJ, Naing A, Falchook GS, Fu S, Kim KB, Davies MA, Nguyen LM, George GC, Xu L, Shumaker R, Ren M, Mink J, Bedell C, Andresen C, Sachdev P, O'Brien JP, Nemunaitis J. Hong DS, et al. Among authors: nemunaitis j. Clin Cancer Res. 2015 Nov 1;21(21):4801-10. doi: 10.1158/1078-0432.CCR-14-3063. Epub 2015 Jul 13. Clin Cancer Res. 2015. PMID: 26169970 Free PMC article. Clinical Trial.
Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study.
Cunningham CC, Chada S, Merritt JA, Tong A, Senzer N, Zhang Y, Mhashilkar A, Parker K, Vukelja S, Richards D, Hood J, Coffee K, Nemunaitis J. Cunningham CC, et al. Among authors: nemunaitis j. Mol Ther. 2005 Jan;11(1):149-59. doi: 10.1016/j.ymthe.2004.09.019. Mol Ther. 2005. PMID: 15585416 Free article. Clinical Trial.
A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors.
Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, Adams N, Zhang YA, Maples PB, Chen S, Pappen B, Burke J, Ichimaru D, Urata Y, Fujiwara T. Nemunaitis J, et al. Among authors: nemunaitis m. Mol Ther. 2010 Feb;18(2):429-34. doi: 10.1038/mt.2009.262. Epub 2009 Nov 24. Mol Ther. 2010. PMID: 19935775 Free PMC article. Clinical Trial.
A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
Hanley MJ, Gupta N, Venkatakrishnan K, Bessudo A, Sharma S, O'Neil BH, Wang B, van de Velde H, Nemunaitis J. Hanley MJ, et al. Among authors: nemunaitis j. J Clin Pharmacol. 2018 Jan;58(1):114-121. doi: 10.1002/jcph.987. Epub 2017 Aug 7. J Clin Pharmacol. 2018. PMID: 28783865 Clinical Trial.
Oncolytic viruses for induction of anti-tumor immunity.
Tong AW, Senzer N, Cerullo V, Templeton NS, Hemminki A, Nemunaitis J. Tong AW, et al. Among authors: nemunaitis j. Curr Pharm Biotechnol. 2012 Jul;13(9):1750-60. doi: 10.2174/138920112800958913. Curr Pharm Biotechnol. 2012. PMID: 21740355 Review.
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma.
Eager RM, Cunningham CC, Senzer NN, Stephenson J Jr, Anthony SP, O'Day SJ, Frenette G, Pavlick AC, Jones B, Uprichard M, Nemunaitis J. Eager RM, et al. Among authors: nemunaitis j. BMC Cancer. 2009 Jul 30;9:263. doi: 10.1186/1471-2407-9-263. BMC Cancer. 2009. PMID: 19643020 Free PMC article. Clinical Trial.
392 results